Back

Lakefront Biotherapeutics rebrands and acquires Ouro Medicines assets with Gilead

Verifying
  • Lakefront Biotherapeutics rebranded and acquired Ouro Medicines' assets with Gilead.
  • €2.24 billion in liquidity is available to support clinical trials for gamgertamig.
  • The transaction created a new drug development platform for Lakefront Biotherapeutics.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.